Enzalutamide 80mg (14 Tablets) in Kenya

Overview

Enzalutamide 80mg is an androgen receptor inhibitor prescribed for metastatic castration-resistant prostate cancer (mCRPC) and non-metastatic castration-resistant prostate cancer (nmCRPC). It blocks androgen receptors, slowing cancer progression and extending survival. Each pack contains 14 tablets (80mg each) and requires strict oncologist supervision due to significant risks.

Composition

• Active Ingredient: Enzalutamide 80mg per tablet.
• Form: White, capsule-shaped, film-coated tablets.
• Inactive Ingredients: Microcrystalline cellulose, croscarmellose sodium, magnesium stearate.

Side Effects

Common

• Fatigue, hot flashes, hypertension, diarrhea.
• Decreased appetite, weight loss, joint pain.

Serious Risks

• Seizures: Discontinue immediately if seizures occur (contraindicated in patients with seizure history).
• Cardiovascular: Hypertension (monitor BP monthly), QT prolongation.
• Hepatotoxicity: Elevated liver enzymes (discontinue if ALT/AST >5x ULN).
• Falls/Fractures: Due to dizziness or seizures.

How to Use

• Dosage: 160mg daily (four 80mg tablets taken together).
• Administration: Once daily at the same time, with or without food. Swallow whole; do not crush/chew.
• Missed Dose: Take within 12 hours; skip if >12 hours late.
• Monitoring:
  • Monthly PSA (first 3 months), then every 3 months.
  • Liver enzymes (ALT/AST) every 2 months.
  • Seizure risk assessment (baseline and ongoing).

Frequently Asked Questions

1. Is it available over-the-counter?
   No – prescription-only by oncologists.

2. Does NHIF cover it?
   Partially – requires pre-approval, oncologist report, and co-payment (30–50%).

3. Are there cheaper alternatives?
   Yes – Abiraterone (KES 50,000–80,000/month) or Docetaxel (chemotherapy; KES 20,000–40,000/cycle).

4. Can it cure prostate cancer?
   No – it slows progression but is not curative.

5. What if seizures occur?
   Stop immediately and seek emergency care. Do not restart.

Conclusion

Enzalutamide 80mg is a critical treatment for advanced prostate cancer in Kenya, offering significant survival benefits but requiring rigorous monitoring due to risks like seizures and hepatotoxicity. Access remains challenging due to high costs (KES 280,000–400,000/month) and limited availability outside major cities. Patients must work closely with oncologists for safe use, leveraging NHIF partial coverage or NGO subsidies where possible. Regular PSA, liver function, and cardiovascular monitoring are essential. While not curative, it provides a vital option for extending survival and improving quality of life in castration-resistant prostate cancer.